Devonian Health Group Announces Grant of Stock Options

Core Viewpoint - Devonian Health Group Inc. has announced the grant of stock options to its directors, employees, and consultants as part of its compensation strategy, reflecting the company's ongoing commitment to incentivize key personnel in the biopharmaceutical sector focused on inflammatory diseases [1][2][3]. Stock Options Grant - The Board of Directors approved the granting of a total of 2,948,056 stock options, with 2,798,056 options allocated to directors at an exercise price of $0.18, valid for 10 years [2]. - Additionally, 385,950 stock options were granted to employees as performance bonuses, with a vesting schedule of 25% on the grant date and 25% per year for the next three years [3]. Product Development - Devonian's flagship product, Thykamine™, is designed for the prevention and treatment of inflammatory and oxidative stress-related health conditions, including ulcerative colitis and atopic dermatitis, supported by extensive clinical studies [4]. - The company operates under the SUPREX™ platform, which is patented in multiple regions, enhancing its competitive edge in the biopharmaceutical market [4]. Company Overview - Devonian Health Group Inc. is a clinical-stage pharmaceutical company established in 2015, focusing on innovative treatments for autoimmune inflammatory conditions [5][7]. - The company also develops high-value cosmeceutical products and has a subsidiary, Altius, dedicated to selling prescription pharmaceuticals in Canada [6].